CheckMyRecalls

Breckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release…

Breckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release Capsules

Published
13 Aug 2025
Units affected
1,829 60-count bottles
Agency
FDA
Country
United States

The hazard

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above safety assessment limit

Classification: Class II — this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.

What to do

Do not stop a prescribed medicine without talking to your doctor or pharmacist first. Ask them about a replacement, and return the recalled product to the pharmacy.

  • Check the lot number on the box or bottle.
  • Talk to your pharmacist or doctor before stopping any prescribed medicine.
  • Return the product to the pharmacy for safe disposal.
Read the official FDA notice

Product details

Duloxetine Delayed-Release Capsules, USP, 60mg, 1,000-count bottles, Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Distributed by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922. NDC 51991-748-10.

Brand / company
Breckenridge Pharmaceutical, Inc.
Codes / lots
Lot: 230836C, Exp.: 02/28/2026
Distribution
U.S Nationwide
Recall status
Ongoing

Source: U.S. Food and Drug Administration, published 13 Aug 2025. CheckMyRecalls reproduces the official notice in summary; always confirm the details with the original notice.